LMNA mutations account for 6.2% of familial DCM in Norway and are associated with high penetrance, frequent arrhythmias, and a high rate of heart transplantation, emphasizing the need for early family screening.
No takes yet. Share an insight, caveat, or question.
Supports LMNA screening consideration in familial DCM; leaves open prospective validation of penetrance and transplant risk.
Hasselberg et al. (2017) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: